Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS
Study sponsor: Brainstorm-Cell Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-03-11Actual
Enrollment · participants23Actual
Source updated2023-12-04Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.